Clinical trials · Washington, D.C., DC
Small Cell Lung Carcinoma clinical trials in Washington, D.C.
We’re tracking 116 recruiting small cell lung carcinoma studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Bethesda, MarylandAges 18 years+ - NCT06400472RecruitingPhase 1
Study of drug Sofe-M for advanced solid tumors
This trial tests a new drug (Sofe-M) for people with certain advanced solid tumors, including ovarian, endometrial, cervical, lung, breast, pancreatic, or colorectal cancers. The goal is to find the best dose and see how well it works, potentially offering a new treatment option.
Falls Church, VirginiaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Rockville, MarylandAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Rockville, MarylandAges 18 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Rockville, MarylandAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Fairfax, VirginiaAges 18–99 - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Fairfax, VirginiaAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Fairfax, VirginiaAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Fairfax, VirginiaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Fairfax, VirginiaAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Fairfax, VirginiaAges 18 years+ - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Fairfax, VirginiaAges 18 years+ - NCT07784959RecruitingPhase 1
Study of NXP900 with lorlatinib for ALK-positive lung cancer
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
Fairfax, VirginiaAges Any age - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Fairfax, VirginiaAges 19 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Fairfax, VirginiaAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Fairfax, VirginiaAges 18 years+ - NCT06515990RecruitingPhase 1/Phase 2
DM005 for Advanced Solid Tumors
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
Fairfax, VirginiaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Fairfax, VirginiaAges 18 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Fairfax, VirginiaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Fairfax, VirginiaAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+
Hear when a new Small Cell Lung Carcinoma trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Small Cell Lung Carcinoma trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting small cell lung carcinoma studies listed above.
- NEXT Virginia · 8 studies
- Virginia Cancer Specialists · 6 studies
- NEXT Oncology · 4 studies
- Maryland Oncology Hematology, P.A. · 2 studies
- Inova Fairfax Hospital
- Inova Schar Cancer Institute
- Johns Hopkins University of Medicine
- Maryland Oncology Hematology
What taking part in a small cell lung carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there small cell lung carcinoma clinical trials near Washington, D.C.?
- Yes. We're currently tracking 116 recruiting small cell lung carcinoma studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung carcinoma study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung carcinoma studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.